Capmatinib hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for capmatinib hydrochloride and what is the scope of freedom to operate?
Capmatinib hydrochloride
is the generic ingredient in one branded drug marketed by Novartis Pharm and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Capmatinib hydrochloride has one hundred and seventy-five patent family members in forty-four countries.
One supplier is listed for this compound.
Summary for capmatinib hydrochloride
International Patents: | 175 |
US Patents: | 5 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 24 |
DailyMed Link: | capmatinib hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for capmatinib hydrochloride
Generic Entry Date for capmatinib hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for capmatinib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Yonsei University | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
Southwest Oncology Group | Phase 2 |
Pharmacology for capmatinib hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 7002587 | ⤷ Try a Trial | |
Israel | 276928 | אימידזוטריאזינים ואימידזופירימידינים כמעכבי קינאז (Imidazotriazines and imidazopyrimidines as kinase inhibitors) | ⤷ Try a Trial |
European Patent Office | 2099447 | IMIDAZOTRIAZINES ET IMIDAZOPYRIMIDINES UTILISÉES EN TANT QU'INHIBITEURS DE KINASES (IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS) | ⤷ Try a Trial |
Netherlands | 301209 | ⤷ Try a Trial | |
Japan | 6105653 | ⤷ Try a Trial | |
Norway | 20200077 | Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer | ⤷ Try a Trial |
Australia | 2009249154 | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for capmatinib hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3172209 | 22C1058 | France | ⤷ Try a Trial | PRODUCT NAME: CAPMATINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SEL DE DICHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1650 20220621 |
2099447 | C202230061 | Spain | ⤷ Try a Trial | PRODUCT NAME: CAPMATINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1650; DATE OF AUTHORISATION: 20220620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1650; DATE OF FIRST AUTHORISATION IN EEA: 20220620 |
2099447 | 53/2022 | Austria | ⤷ Try a Trial | PRODUCT NAME: CAPMATINIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/22/1650 (MITTEILUNG) 20220621 |
2099447 | 2290050-0 | Sweden | ⤷ Try a Trial | PRODUCT NAME: CAPMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/22/1650 20220621 |
2099447 | C20220044 00389 | Estonia | ⤷ Try a Trial | PRODUCT NAME: KAPMATINIIB;REG NO/DATE: EU/1/22/1650; 21.06.2022 |
2099447 | CA 2022 00053 | Denmark | ⤷ Try a Trial | PRODUCT NAME: CAPMATINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/22/1650 20220621 |
2099447 | PA2022527 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: KAPMATINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/22/1650 20220620 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.